Cancers, Vol. 12, Pages 1535: TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival

Cancers, Vol. 12, Pages 1535: TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival Cancers doi: 10.3390/cancers12061535 Authors: Donald Freudenstein Cassandra Litchfield Franco Caramia Gavin Wright Benjamin J. Solomon David Ball Simon P. Keam Paul Neeson Ygal Haupt Sue Haupt Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved management. Using a bioinformatics approach across non-small cell lung cancer (NSCLC) subtypes, we identified where patient sex, mutation of the major tumor suppressor gene, Tumour protein P53 (TP53), and immune signatures stratified outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), among datasets of The Cancer Genome Atlas (TCGA). We exposed sex and TP53 gene mutations as prognostic for LUAD survival. Longest survival in LUAD occurred among females with wild-type (wt) TP53 genes, high levels of immune infiltration and enrichment for pathway signatures of Interferon Gamma (INF-γ), Tumour Necrosis Factor (TNF) and macrophages-monocytes. In contrast, poor survival in men with LUAD and wt TP53 genes corresponded with enrichment of Transforming Growth Factor Beta 1 (TGFB1, hereafter TGF-β) and wo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research